Arcturus Therapeutics Holdings Inc

(NASDAQ:ARCT)

Latest On Arcturus Therapeutics Holdings Inc (ARCT):

Date/Time Type Description Signal Details
2023-05-11 16:55 ESTNewsArcturus raised to Buy at H.C. Wainwright on prospects for COVID shotN/A
2023-05-10 00:15 ESTNewsArcturus Therapeutics GAAP EPS of $1.87 beats by $1.46, revenue of $80.29M beats by $30.83MN/A
2023-05-10 00:14 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) Q1 2023 Earnings Call TranscriptN/A
2023-05-08 21:14 ESTNewsArcturus Therapeutics Q1 2023 Earnings PreviewN/A
2023-04-12 00:46 ESTNewsUnlocking Arcturus' Potential And De-Risking Through PartnershipsN/A
2023-03-29 09:24 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Call TranscriptN/A
2023-03-28 18:53 ESTNewsArcturus Therapeutics EPS of $4.33, revenue of $160.29M beats by $79.77MN/A
2023-03-28 18:53 ESTNewsArcturus Therapeutics up 21% after hours on quarterly beats, cash runway extensionN/A
2023-03-28 03:22 ESTNewsArcturus Therapeutics Q4 2022 Earnings PreviewN/A
2023-02-01 14:01 ESTNewsArcturus' mRNA Platform: The Future Of Quick And Efficient Vaccine DeliveryN/A
2023-01-31 12:48 ESTNewsArcturus' mRNA therapy for cystic fibrosis cleared for early-stage trial in New ZealandN/A
2022-11-15 15:34 ESTNewsArcturus Therapeutics Should Benefit From A Variety Of Positive DevelopmentsN/A
2022-11-11 06:26 ESTNewsArcturus downgraded at Baird on delayed catalyst and uncertainties in CSL dealN/A
2022-11-10 13:18 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 20:42 ESTNewsArcturus Therapeutics GAAP EPS of -$1.33 beats by $0.44, revenue of $13.4M beats by $9.31MN/A
2022-11-09 02:35 ESTNewsArcturus Therapeutics Q3 2022 Earnings PreviewN/A
2022-11-03 23:27 ESTNewsArcturus Therapeutics upgraded to buy at Citi on CSL Seqirus collaborationN/A
2022-11-02 13:47 ESTNewsArcturus Therapeutics announces collaboration with CSL SeqirusN/A
2022-11-02 13:47 ESTNewsAMD, JD and BILI are among pre market gainersN/A
2022-09-01 02:13 ESTNewsArcturus rises 6% on $63.2M award from U.S. government for mRNA vaccineN/A
2022-08-10 12:44 ESTNewsAcrturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-10 12:44 ESTNewsArcturus Therapeutics downgraded to underperform at Raymond James on program setbacksN/A
2022-08-09 18:58 ESTNewsArcturus Therapeutics GAAP EPS of -$0.82 beats by $1.04, revenue of $27.09M beats by $24.58MN/A
2022-08-08 19:55 ESTNewsArcturus Therapeutics Q2 2022 Earnings PreviewN/A
2022-06-22 15:45 ESTNewsArcturus gains 8% yesterday on takeover interest, blog report claimsN/A
2022-06-07 08:37 ESTNewsArcturus: Potential Based On Rare Disease Therapy ARCT-810N/A
2022-05-10 02:23 ESTNewsArcturus Therapeutics GAAP EPS of -$1.94 misses by $0.63, revenue of $5.24M misses by $1.84MN/A
2022-05-10 02:22 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-06 19:53 ESTNewsArcturus Therapeutics Q1 2022 Earnings PreviewN/A
2022-04-25 17:54 ESTNewsArcturus: Biotech With Great Potential In Covid-19 Vaccine SpaceN/A
2022-04-21 15:26 ESTNewsArcturus cut to Neutral at Citi on COVID vaccine ARCT-154 'too risky' path aheadN/A
2022-04-21 01:19 ESTNewsArcturus falls even as Piper Sandler backs COVID-19 vaccine dataN/A
2022-04-20 10:11 ESTNewsArcturus announces 95% overall efficacy for mRNA-based COVID-19 shotN/A
2022-03-22 17:29 ESTNewsArcturus gains with positive views from Piper Sandler on COVID-19 boosterN/A
2022-03-01 03:13 ESTNewsArcturus Therapeutics GAAP EPS of -$1.47 beats by $0.16, revenue of $5.8M misses by $5.85MN/A
2022-03-01 03:13 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-28 07:15 ESTNewsArcturus Therapeutics Q4 2021 Earnings PreviewN/A
2022-01-25 09:15 ESTNewsArcturus says messenger RNA vaccines raised antibody levels as boosters against OmicronN/A
2022-01-24 17:14 ESTNewsArcturus Therapeutics falls 9% amid announcement of COVID-19 booster study dataN/A
2021-12-16 23:03 ESTNewsArcturus gains after announcing early data from COVID-19 booster studyN/A
2021-11-29 02:58 ESTNewsArcturus: Emerging Covid Variants May Provide A Raison D'êTreN/A
2021-11-23 17:34 ESTNewsNanotechnology ETF is launched by Direxion SharesN/A
2021-11-09 04:02 ESTNewsArcturus Therapeutics EPS misses by $0.72, misses on revenueN/A
2021-11-09 04:02 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-08 07:45 ESTNewsArcturus Therapeutics Q3 2021 Earnings PreviewN/A
2021-10-26 12:35 ESTNewsPiper Sandler initiates Arcturus with a buy on COVID vaccine included in WHO trialN/A
2021-10-12 20:39 ESTNewsVietnam health agency OKs phase 3b of Arcturus trial of SARS-CoV-2 vaccineN/A
2021-10-07 05:05 ESTNewsMerck eyeing more M&A deals as patent cliff for key cancer drug nears - FTN/A
2021-09-22 21:42 ESTNewsArcturus gets approval for ARCT-154 COVID-19 vaccine trials in VietnamN/A
2021-09-21 12:24 ESTNewsArcturus Therapeutics (ARCT) Investor Presentation - SlideshowN/A

About Arcturus Therapeutics Holdings Inc (ARCT):

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

See Advanced Chart

General

  • Name Arcturus Therapeutics Holdings Inc
  • Symbol ARCT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 118
  • Last Split Factor1:7
  • Last Split Date2017-11-16
  • Fiscal Year EndDecember
  • IPO Date2020-04-16
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.arcturusrx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 109.33
  • Price/Book (Most Recent Quarter) 3.4
  • Enterprise Value Revenue 86.83
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.67
  • Next Year EPS Estimate $7.69
  • Next Quarter EPS Estimate -$0.70
  • Operating Margin -750%
  • Return on Assets -16%
  • Return on Equity -34%
  • Revenue 9.54 million
  • Earnings Per Share -$1.26
  • Revenue Per Share $0.47
  • Gross Profit -48307000
  • Quarterly Earnings Growth -24.6%
View More

Highlights

  • Market Capitalization 1.27 billion
  • EBITDA -11472000
  • PE Ratio -7.9
  • Analyst Target Price $86.15
  • Book Value Per Share $15.14
View More

Share Statistics

  • Shares Outstanding 26.28 million
  • Shares Float 21.5 million
  • % Held by Insiders 1843%
  • % Held by Institutions 70.46%
  • Shares Short 3.19 million
  • Shares Short Prior Month 2.59 million
  • Short Ratio 3
  • Short % of Float 15%
  • Short % of Shares Outstanding 12%
View More

Technicals

  • Beta 2.93
  • 52 Week High $129.71
  • 52 Week Low $11.71
  • 50 Day Moving Average 62.88
  • 200 Day Moving Average 61.73
View More

Dividends

  • Dividend Date 2017-11-16
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Arcturus Therapeutics Holdings Inc (ARCT) Dividend Calendar:

ARCT's last dividend payment was made to shareholders on November 16, 2017.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Arcturus Therapeutics Holdings Inc (ARCT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-01$N/A-$1.25-$0.86-45.33%
2020-09-302020-11-09$N/A-$0.92-$0.49-87.49%
2020-06-302020-08-10$2.32 million-$0.55-$0.550.31%
2020-03-312020-05-07$2.65 million-$0.67-$0.59-13.83%
2019-12-312020-03-11$2.97 million-$0.76-$0.51-49.61%
2019-09-302019-11-08$3.32 million-$0.56-$0.46-20.87%
2019-06-302019-08-14$10.15 million-$0.07-$0.6188.6%
2019-03-312019-05-13$4.35 million-$0.68-$0.60-13.96%
2018-12-312019-03-18$7.58 million-$0.09-$0.5282.69%
2018-09-302018-11-07$3.42 million-$0.42-$0.35-20%
2018-06-302018-09-28$2.39 million-$0.99-$0.34-191.18%
2018-03-312018-05-14$2.38 million-$1.08-$0.46-134.78%
2017-12-312018-02-15$2.02 million-$0.11
2017-09-302017-11-09$3.3 million-$0.70-$2.6673.68%
2017-06-302017-08-11$3.76 million-$0.91-$0.943.19%
2017-03-312017-05-30$3.92 million-$0.91-$1.2627.78%
2016-12-312017-02-15$20.38 million-$1.54-$1.9018.95%
2016-09-302016-11-15$N/A-$1.96-$1.80-8.89%
2016-06-302016-08-30$N/A-$1.47-$1.533.92%
2016-03-312016-05-16$N/A-$1.26-$1.5116.56%
2015-12-312016-02-17-$1.40-$1.6816.67%
2015-09-302015-11-12-$0.20-$0.3135.48%
2015-06-302015-08-13-$0.24-$0.2917.24%
2015-03-312015-05-06-$0.26-$0.2910.34%
2014-12-312015-02-12-$0.50-$0.6016.67%
2014-09-302014-11-17-$0.77-$0.56-37.5%
2014-06-302014-08-11-$0.57-$0.53-7.55%
2014-03-312014-05-15-$3.71-$2.85-30.18%
2013-12-312014-02-13-$3.15-$2.20-43.18%
2013-09-302013-11-07-$1.96-$0.63-211.11%
2013-06-302013-08-06-$0.42-$0.420%

Arcturus Therapeutics Holdings Inc (ARCT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Arcturus Therapeutics Holdings Inc (ARCT) Chart:

Arcturus Therapeutics Holdings Inc (ARCT) News:

Below you will find a list of latest news for Arcturus Therapeutics Holdings Inc (ARCT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Arcturus Therapeutics Holdings Inc (ARCT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-2050CALL0 0601.05TRUE00
2025-06-207.50CALL0 12273.71TRUE00
2025-06-20103.2CALL0 42114.14TRUE00
2025-06-2012.50.98CALL0 29386.73FALSE00
2025-06-20150.15CALL51 26995.51FALSE0.150
2025-06-2017.50.05CALL0 560177.05FALSE00
2025-06-20200.02CALL1 1906117.89FALSE0.020
2025-06-2022.50CALL0 63159.89FALSE00
2025-06-20250.03CALL0 401163.26FALSE00
2025-06-20300.38CALL1 53313.64FALSE0.380
2025-06-20350CALL0 6366.47FALSE00
2025-06-2050PUT0 0382.74FALSE00
2025-06-207.50PUT0 55258.56FALSE00
2025-06-20100PUT0 42243.16FALSE00
2025-06-2012.50.9PUT0 180113.47TRUE00
2025-06-20152.32PUT0 164124.36TRUE00
2025-06-2017.55.65PUT10 273118TRUE5.650
2025-06-20200PUT0 0266.67TRUE00
2025-06-2022.50PUT0 1217.27TRUE00
2025-06-20250PUT0 1253.45TRUE00
2025-06-20300PUT0 0477.76TRUE00
2025-06-20350PUT0 0427.65TRUE00
2025-07-182.50CALL0 0633.03TRUE00
2025-07-1850CALL0 0368.41TRUE00
2025-07-187.50CALL0 094.61TRUE00
2025-07-18102.7CALL1 0102.57TRUE2.70
2025-07-1812.51.79CALL0 5091.81FALSE00
2025-07-18150.6CALL5 12293.22FALSE0.60
2025-07-1817.50.45CALL0 14191.82FALSE00
2025-07-18200.12CALL1 094.52FALSE0.120
2025-07-1822.50CALL0 0153.62FALSE00
2025-07-18250CALL0 0166.89FALSE00
2025-07-182.50PUT0 0390.01FALSE00
2025-07-1850PUT0 0310.12FALSE00
2025-07-187.50PUT0 0131.33FALSE00
2025-07-18100.7PUT1 299.37FALSE0.70
2025-07-1812.51.51PUT0 786.76TRUE00
2025-07-18153.05PUT0 277.95TRUE00
2025-07-1817.54.93PUT0 2121.13TRUE00
2025-07-18200PUT0 0115.56TRUE00
2025-07-1822.50PUT0 0150.18TRUE00
2025-07-18250PUT0 0161TRUE00
2025-09-192.50CALL0 5180.63TRUE00
2025-09-1950CALL0 1232.74TRUE00
2025-09-197.50CALL0 290.6TRUE00
2025-09-19100CALL0 7399.18TRUE00
2025-09-1912.52.5CALL0 3556.04FALSE00
2025-09-19151.95CALL0 4561.69FALSE00
2025-09-1917.50.9CALL0 19468.22FALSE00
2025-09-19200.5CALL0 24783.81FALSE00
2025-09-1922.50CALL0 290.78FALSE00
2025-09-19250.2CALL0 24100.57FALSE00
2025-09-19300CALL0 2116.66FALSE00
2025-09-19350.1CALL0 227129.58FALSE00
2025-09-192.50PUT0 0249.55FALSE00
2025-09-1950PUT0 5186.41FALSE00
2025-09-197.50PUT0 16148.12FALSE00
2025-09-19100PUT0 13571.95FALSE00
2025-09-1912.52.25PUT0 6391.56TRUE00
2025-09-19153.9PUT10 14574.12TRUE3.90
2025-09-1917.50PUT0 5185.81TRUE00
2025-09-19200PUT0 075.29TRUE00
2025-09-1922.50PUT0 082.9TRUE00
2025-09-19250PUT0 087.49TRUE00
2025-09-19300PUT0 0137.1TRUE00
2025-09-19350PUT0 0177.23TRUE00
2025-12-192.50CALL0 0169.23TRUE00
2025-12-1950CALL0 0128.72TRUE00
2025-12-197.56CALL0 988.03TRUE00
2025-12-19104.3CALL0 3578.71TRUE00
2025-12-1912.53.18CALL0 381.81FALSE00
2025-12-19152.05CALL0 23679.84FALSE00
2025-12-1917.51.45CALL0 1278.55FALSE00
2025-12-19201.3CALL0 3475.8FALSE00
2025-12-1922.50.84CALL1 484.8FALSE0.840
2025-12-192.50PUT0 0184.17FALSE00
2025-12-1950PUT0 0222.81FALSE00
2025-12-197.50PUT0 593.11FALSE00
2025-12-19101.63PUT0 7468.24FALSE00
2025-12-1912.52.8PUT0 3673.42TRUE00
2025-12-19150PUT0 079.04TRUE00
2025-12-1917.50PUT0 075.99TRUE00
2025-12-19200PUT0 078.5TRUE00
2025-12-1922.50PUT0 076.66TRUE00

Latest ARCT Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST7$13.15
Jun 13, 2022 7:59 PM EST100$13.18
Jun 13, 2022 7:59 PM EST200$13.19
Jun 13, 2022 7:59 PM EST200$13.2
Jun 13, 2022 7:59 PM EST100$13.2

Arcturus Therapeutics Holdings Inc (ARCT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000746/0001193805-20-000746-index.htm
2019-06-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1768224/000000000019010412/0000000000-19-010412-index.htm
2020-05-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1768224/000000000020004351/0000000000-20-004351-index.htm
2019-06-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319018228/0000899243-19-018228-index.htm
2019-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319022258/0000899243-19-022258-index.htm
2019-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319022418/0000899243-19-022418-index.htm
2019-08-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319022619/0000899243-19-022619-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319023531/0000899243-19-023531-index.htm
2019-09-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319023769/0000899243-19-023769-index.htm
2019-09-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319024193/0000899243-19-024193-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319026109/0000899243-19-026109-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319026116/0000899243-19-026116-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319026123/0000899243-19-026123-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319026159/0000899243-19-026159-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319026165/0000899243-19-026165-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319028631/0000899243-19-028631-index.htm
2019-12-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319028803/0000899243-19-028803-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005379/0000899243-20-005379-index.htm
2020-02-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005382/0000899243-20-005382-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005383/0000899243-20-005383-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005386/0000899243-20-005386-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005387/0000899243-20-005387-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005389/0000899243-20-005389-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320016049/0000899243-20-016049-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320016050/0000899243-20-016050-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320016410/0000899243-20-016410-index.htm
2020-09-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320024363/0000899243-20-024363-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320026884/0000899243-20-026884-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320030320/0000899243-20-030320-index.htm
2020-04-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1768224/000092963820000538/0000929638-20-000538-index.htm
2020-09-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1768224/000110465920104394/0001104659-20-104394-index.htm
2020-10-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1768224/000110465920113789/0001104659-20-113789-index.htm
2019-03-18S-4Registration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1768224/000119312519077140/0001193125-19-077140-index.htm
2019-04-11S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1768224/000119312519104005/0001193125-19-104005-index.htm
2019-04-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1768224/000119312519104054/0001193125-19-104054-index.htm
2019-04-12424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1768224/000119312519105243/0001193125-19-105243-index.htm
2019-06-148-K12BNotification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b)https://www.sec.gov/Archives/edgar/data/1768224/000119312519173808/0001193125-19-173808-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519176112/0001193125-19-176112-index.htm
2019-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519176908/0001193125-19-176908-index.htm
2019-06-21S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1768224/000119312519178934/0001193125-19-178934-index.htm
2019-07-25CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1768224/000119312519202684/0001193125-19-202684-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519205403/0001193125-19-205403-index.htm
2019-08-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119312519212073/0001193125-19-212073-index.htm
2019-08-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519212082/0001193125-19-212082-index.htm
2019-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119312519212590/0001193125-19-212590-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519212594/0001193125-19-212594-index.htm
2019-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519221871/0001193125-19-221871-index.htm
2019-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519245891/0001193125-19-245891-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519252227/0001193125-19-252227-index.htm
2019-09-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119312519257362/0001193125-19-257362-index.htm
2019-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519257389/0001193125-19-257389-index.htm
2019-10-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1768224/000119312519259220/0001193125-19-259220-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519280541/0001193125-19-280541-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519287260/0001193125-19-287260-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519287407/0001193125-19-287407-index.htm
2019-12-12S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1768224/000119312519312823/0001193125-19-312823-index.htm
2020-05-22SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1768224/000119312520150308/0001193125-20-150308-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312520164097/0001193125-20-164097-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380519000694/0001193805-19-000694-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000030/0001193805-20-000030-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000295/0001193805-20-000295-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000335/0001193805-20-000335-index.htm
2020-03-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000411/0001193805-20-000411-index.htm
2020-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000412/0001193805-20-000412-index.htm
2020-04-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000486/0001193805-20-000486-index.htm
2020-04-16S-3MEFRegistration adding securities to prior Form S-3 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000491/0001193805-20-000491-index.htm
2020-04-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000494/0001193805-20-000494-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000535/0001193805-20-000535-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000565/0001193805-20-000565-index.htm
2020-05-08S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1768224/000119380520000569/0001193805-20-000569-index.htm
2020-05-18CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000600/0001193805-20-000600-index.htm
2020-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000622/0001193805-20-000622-index.htm
2020-05-22S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1768224/000119380520000627/0001193805-20-000627-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000704/0001193805-20-000704-index.htm
2020-06-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000721/0001193805-20-000721-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000742/0001193805-20-000742-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000743/0001193805-20-000743-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000744/0001193805-20-000744-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000745/0001193805-20-000745-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000746/0001193805-20-000746-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000886/0001193805-20-000886-index.htm
2020-07-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000900/0001193805-20-000900-index.htm
2020-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000902/0001193805-20-000902-index.htm
2020-07-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000907/0001193805-20-000907-index.htm
2020-08-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000939/0001193805-20-000939-index.htm
2020-08-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000940/0001193805-20-000940-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000987/0001193805-20-000987-index.htm
2020-08-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001021/0001193805-20-001021-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001022/0001193805-20-001022-index.htm
2020-08-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001052/0001193805-20-001052-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001229/0001193805-20-001229-index.htm
2020-10-02PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001230/0001193805-20-001230-index.htm
2020-10-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001272/0001193805-20-001272-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001274/0001193805-20-001274-index.htm
2019-06-253Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000120919119039011/0001209191-19-039011-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000120919120031641/0001209191-20-031641-index.htm
2019-06-21S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1768224/000156459019023153/0001564590-19-023153-index.htm
2019-06-26SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1768224/000156459019023496/0001564590-19-023496-index.htm
2019-06-26S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1768224/000156459019023504/0001564590-19-023504-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1768224/000156459019032166/0001564590-19-032166-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1768224/000156459019042017/0001564590-19-042017-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1768224/000156459020011037/0001564590-20-011037-index.htm
2020-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000156459020017147/0001564590-20-017147-index.htm
2020-04-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000156459020017549/0001564590-20-017549-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1768224/000156459020023633/0001564590-20-023633-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1768224/000156459020038980/0001564590-20-038980-index.htm
2019-04-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1768224/999999999519000693/9999999995-19-000693-index.htm
2019-07-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1768224/999999999519001724/9999999995-19-001724-index.htm
2020-05-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1768224/999999999520001236/9999999995-20-001236-index.htm
2020-06-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1768224/999999999520001665/9999999995-20-001665-index.htm
2019-07-18CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1768224/999999999719006174/9999999997-19-006174-index.htm
2020-02-03SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1768224/999999999720000424/9999999997-20-000424-index.htm
2020-02-24SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1768224/999999999720000993/9999999997-20-000993-index.htm

Arcturus Therapeutics Holdings Inc (ARCT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arcturus Therapeutics Holdings Inc (ARCT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1843%
Institutional Ownership: 7046%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-08-29Joseph E PaynePresident and CEOBuy5,000.0011.2256,100.001,474,097.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319022619/0000899243-19-022619-index.htm
2020-06-10Joseph E PaynePresident and CEOBuy1,000.0031.6931,690.001,475,097.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320016050/0000899243-20-016050-index.htm
2019-09-13Magda MarquetDirectorBuy2,300.0010.5824,334.0022,720.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319023769/0000899243-19-023769-index.htm
2019-08-23ANDY SASSINEChief Financial OfficerBuy10,000.0010.90109,000.00247,596.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319022418/0000899243-19-022418-index.htm
2019-12-03ANDY SASSINEChief Financial OfficerBuy10,000.0010.00100,000.00257,596.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319028631/0000899243-19-028631-index.htm
2019-12-05ANDY SASSINEChief Financial OfficerBuy5,649.009.7354,964.77268,245.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319028803/0000899243-19-028803-index.htm
2020-06-10ANDY SASSINEChief Financial OfficerBuy5,000.0029.74148,700.00273,245.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320016049/0000899243-20-016049-index.htm
2020-05-20Ultragenyx Pharmaceutical Inc.DirectorBuy600,000.0016.009,600,000.003,000,000.00https://www.sec.gov/Archives/edgar/data/1768224/000120919120031641/0001209191-20-031641-index.htm
2019-08-19PETER C FARRELLDirectorBuy4,681.0011.0251,584.6238,523.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319022258/0000899243-19-022258-index.htm
2019-08-20PETER C FARRELLDirectorBuy4,432.0010.8548,087.2042,955.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319022258/0000899243-19-022258-index.htm
2019-09-12Keith C KummerfeldOfficerBuy500.0010.695,346.70500.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319023531/0000899243-19-023531-index.htm
2020-11-02Pad ChivukulaChief Scientific Officer & COOSell10,000.0055.28552,800.00702,548.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320030320/0000899243-20-030320-index.htm
2020-10-01Pad ChivukulaChief Scientific Officer & COOSell10,000.0042.83428,300.00712,548.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320026884/0000899243-20-026884-index.htm
2020-09-03Pad ChivukulaChief Scientific Officer & COOSell10,000.0045.16451,600.00722,548.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320024363/0000899243-20-024363-index.htm
2020-06-12Keith C KummerfeldOfficerBuy450.0033.3314,998.50950.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320016410/0000899243-20-016410-index.htm